Could a diabetes drug help Veterans' blood vessels and mobility?
NCT ID NCT07060417
First seen May 30, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase 2 trial will test whether empagliflozin (Jardiance), a drug already used for diabetes, can improve blood vessel health and exercise capacity in 52 veterans with non-diabetic chronic kidney disease. Participants will take either the drug or a placebo for a period, and researchers will measure changes in artery function and leg blood flow. The goal is to see if this drug offers benefits beyond blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-DIABETIC CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (Jardiance)
What this could lead to
If successful, this could show that empagliflozin helps protect blood vessels and improve physical function in people with chronic kidney disease who do not have diabetes.
What could go wrong
This is a small, early-phase trial (52 participants) focused on short-term changes in blood vessel function, not long-term kidney outcomes. Results may not apply to all CKD patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.